United States Patent 8,354,427: Scope, Claims, Expiration, and Ivacaftor Patent Landscape
U.S. Patent No. 8,354,427 protects a narrow method of using ivacaftor, also known as VX-770, to treat or reduce the severity of cystic fibrosis in patients carrying the R117H mutation in CFTR. The patent does not broadly claim ivacaftor, all CFTR mutations, or all cystic-fibrosis treatments. Its principal commercial relevance is the R117H indication for Kalydeco and products containing ivacaftor.
The patent was issued to Vertex Pharmaceuticals Incorporated on January 15, 2013. Its nominal patent term runs to approximately March 20, 2029, subject to any applicable patent-term adjustment or other term calculation recorded by the USPTO. The relevant FDA Orange Book listing is a method-of-use listing rather than a composition-of-matter listing.
What does U.S. Patent 8,354,427 claim?
The patent has three claims directed to treating cystic fibrosis in a patient whose CFTR protein carries the R117H mutation.
| Claim |
Scope |
Independent or dependent |
| 1 |
Treating or lessening the severity of cystic fibrosis in a patient with an R117H CFTR mutation by administering an effective amount of ivacaftor |
Independent |
| 2 |
Claim 1 where the patient is heterozygous for R117H |
Dependent |
| 3 |
Claim 1 where the patient is homozygous for R117H |
Dependent |
The claimed active ingredient is:
N-(5-hydroxy-2,4-di-tert-butylphenyl)-4-oxo-1H-quinoline-3-carboxamide
That compound is ivacaftor, marketed by Vertex as Kalydeco. The same active ingredient is also included in combination products such as Orkambi, Symdeko and Trikafta, although those products raise separate patent and regulatory questions.
The claims require four core elements:
- A patient with cystic fibrosis.
- CFTR containing the R117H mutation.
- Administration of ivacaftor.
- An amount effective to treat or lessen disease severity.
The claim does not expressly require a particular dose, dosage form, route of administration, treatment duration, age group, genotype combination, or biomarker endpoint.
How broad is claim 1 of Patent 8,354,427?
Claim 1 is narrow by disease-genotype standards but commercially meaningful because it covers the use of a specific drug for a defined CFTR mutation.
Patient limitation
The patient must have a CFTR protein with an R117H mutation. The claim is not limited to a particular second CFTR allele. It therefore encompasses patients with:
- R117H/R117H;
- R117H paired with a different pathogenic mutation;
- R117H paired with a minimal-function mutation; and
- R117H paired with a mutation not separately characterized in the claim.
Claim 1 does not require the patient to be heterozygous or homozygous. Those two genetic states are separately recited in claims 2 and 3.
Drug limitation
The administered compound must be ivacaftor. A structurally different CFTR potentiator would not literally satisfy the drug limitation, even if it produced a similar clinical result.
The claim is therefore not a platform claim covering all potentiators, correctors, amplifiers or stabilizers. It is a drug-specific method claim.
Therapeutic-result limitation
The method must treat or lessen the severity of cystic fibrosis. A purely pharmacokinetic study, diagnostic administration, or administration for an unrelated condition would not naturally satisfy the stated therapeutic purpose.
The phrase “effective amount” is functional. It generally requires an amount capable of producing the claimed therapeutic effect in the treated patient. The claim does not state a numerical dose.
What do claims 2 and 3 add for heterozygous and homozygous R117H patients?
Claim 2 covers heterozygous R117H patients. Claim 3 covers homozygous R117H patients.
Because claim 1 already covers a patient with an R117H mutation without specifying zygosity, claims 2 and 3 provide narrower fallback positions rather than materially expanding the patent’s scope.
| Genotype |
Covered by claim 1? |
Specifically covered |
| R117H/R117H |
Yes |
Claim 3 |
| R117H/another CFTR mutation |
Yes |
Claim 2 if heterozygous |
| R117H/wild-type allele |
Potentially, depending on disease diagnosis and claim construction |
Claim 2 if treated as heterozygous |
| No R117H mutation |
No |
No claim coverage |
The practical value of claims 2 and 3 is prosecution and litigation resilience. If claim 1 were narrowed or challenged, the more specific zygosity claims could provide narrower positions. They do not, however, cover different drugs or additional mutations.
What patent protects ivacaftor itself?
The principal foundational patent family for ivacaftor includes U.S. Patent No. 7,405,323, which covers quinoline compounds and related pharmaceutical uses. That patent is distinct from U.S. Patent No. 8,354,427.
| Patent category |
Representative subject matter |
Commercial purpose |
| Composition patent |
Ivacaftor and related quinoline compounds |
Protects the molecule itself |
| R117H method patent |
Ivacaftor treatment of R117H cystic fibrosis |
Protects a genotype-specific use |
| Formulation patents |
Solid oral dosage forms and pharmaceutical compositions |
Protects product presentation and manufacture |
| Combination patents |
Ivacaftor with CFTR correctors |
Protects combination regimens |
| Manufacturing patents |
Chemical synthesis, intermediates and purification |
Raises production and process barriers |
The composition patent is generally more valuable against a generic ivacaftor product because it can block manufacture, sale and use of the compound across indications. Patent 8,354,427 is narrower. Its primary relevance is a generic or follow-on product that seeks an FDA label expressly covering R117H treatment.
When does U.S. Patent 8,354,427 expire?
The patent has a nominal expiration date in March 2029, based on its relevant priority and filing chronology. The precise enforceable date should be determined from the USPTO patent-term record because patent-term adjustment can alter the expiration date.
The expected exclusivity sequence is:
| Event |
Timing |
| Relevant priority date |
March 20, 2009 |
| Patent grant |
January 15, 2013 |
| Nominal 20-year term endpoint |
Approximately March 20, 2029 |
| FDA-listed method-of-use protection |
Expected to remain relevant until the recorded patent expiration |
| Potential generic exposure |
Before expiration only through an ANDA challenge, license, settlement or non-infringing label |
The patent is not a biologic exclusivity right and does not create a 12-year biologic reference-product exclusivity period. Ivacaftor is a small molecule regulated through the abbreviated new drug application pathway.
What is the Orange Book status of Patent 8,354,427?
Patent 8,354,427 is associated with Kalydeco’s method-of-use protection for cystic fibrosis patients with the R117H mutation. The listing is materially different from an active-ingredient listing.
An Orange Book method-of-use listing generally identifies:
- the approved product;
- the patent number;
- the patent expiration date; and
- a use code describing the approved method.
The FDA-approved Kalydeco labeling includes treatment of cystic fibrosis in patients with specific CFTR mutations that are responsive to ivacaftor, including R117H. FDA labeling identifies ivacaftor as a CFTR potentiator that increases the channel-open probability of CFTR at the cell surface. [2]
The Orange Book listing does not itself determine infringement. It gives an ANDA applicant the regulatory mechanism for challenging the listed patent through a Paragraph IV certification or avoiding the patented use through a section viii statement, where legally available.
How does a Paragraph IV challenge apply to this patent?
A generic applicant seeking approval before the patent expiration date could use one of several approaches.
Paragraph IV certification
The applicant could certify that the patent is invalid, unenforceable or will not be infringed. A Paragraph IV notice would permit the patent holder to bring infringement litigation under the Hatch-Waxman Act.
For this patent, likely challenge theories would include:
- lack of enablement;
- lack of written description;
- obviousness based on prior CFTR potentiator and genotype data;
- indefiniteness of “effective amount” or the disease-treatment language;
- non-infringement based on a label that excludes R117H treatment; and
- non-infringement based on a product not containing ivacaftor.
Section viii statement
If the patent is listed only for a method of use and the generic label omits the R117H indication, an ANDA applicant may attempt a section viii statement. The feasibility of that strategy depends on the exact Orange Book use code, the proposed label and whether the remaining label language would induce infringement.
A “skinny label” does not automatically eliminate risk. If the generic product is marketed with promotional materials, labeling language or instructions that encourage R117H use, the patent holder could assert induced infringement.
Commercial impact
The patent is most vulnerable to a non-infringing-label strategy if:
- the generic seeks approval for non-R117H CFTR mutations;
- the R117H indication can be omitted without undermining the product’s commercial value;
- the Orange Book use code is sufficiently narrow; and
- the generic avoids marketing directed to R117H patients.
The strategy is less attractive if the R117H population is an important part of the product’s demand or if the generic intends to substitute for Kalydeco across the full FDA label.
What formulation patents protect ivacaftor products?
Ivacaftor products may have patent protection beyond the R117H use claim.
Relevant formulation and product issues include:
- tablet composition;
- oral granules;
- dispersible or pediatric dosage forms;
- excipient selection;
- dissolution and bioavailability characteristics;
- fixed-dose combinations with lumacaftor, tezacaftor or elexacaftor; and
- packaging and administration instructions.
A formulation patent must be analyzed separately from Patent 8,354,427. The R117H patent does not require tablets, granules, oral administration or any particular excipient. A generic could potentially avoid formulation claims while still raising method-of-use infringement issues.
The combination products create a separate patent layer:
| Product |
Active ingredients |
Primary patent issue |
| Kalydeco |
Ivacaftor |
Composition, formulation and mutation-specific uses |
| Orkambi |
Lumacaftor/ivacaftor |
Combination, formulation and manufacturing patents |
| Symdeko |
Tezacaftor/ivacaftor |
Combination and regimen patents |
| Trikafta |
Elexacaftor/tezacaftor/ivacaftor |
Combination, formulation, dosing and method patents |
A product containing ivacaftor is not automatically within the scope of every ivacaftor patent. Claim language, FDA labeling and the specific approved indication control.
What is the patent strength of U.S. Patent 8,354,427?
The patent has moderate to strong commercial value for the specific R117H indication, but limited breadth outside that indication.
| Factor |
Assessment |
| Molecule specificity |
Narrow |
| Genotype specificity |
Narrow, limited to R117H |
| Disease specificity |
Cystic fibrosis |
| Dose limitation |
No express numerical dose |
| Formulation limitation |
None |
| Route limitation |
None |
| Zygosity limitation in independent claim |
None |
| Design-around potential |
Moderate to high |
| Value against a full-label ivacaftor generic |
High |
| Value against a non-R117H label |
Lower |
| Value against a different CFTR potentiator |
None on literal claim scope |
The claim benefits from its simple structure. A competing product that administers ivacaftor to treat an R117H patient could satisfy the elements without using Vertex’s tablet formulation or manufacturing process.
The principal weakness is narrow therapeutic coverage. The patent does not stop a competitor from developing:
- a different potentiator for R117H;
- a gene-editing or mRNA approach;
- a corrector-only treatment;
- a different drug for non-R117H mutations; or
- a generic ivacaftor product with a legally effective omission of the R117H use.
Which companies are challenging Kalydeco and ivacaftor exclusivity?
The relevant competitive group includes generic manufacturers that could pursue ivacaftor or Kalydeco ANDAs, as well as branded CFTR-modulator developers.
Public regulatory and patent records should be evaluated product by product because an ANDA applicant may challenge the composition patent, the R117H method patent, a formulation patent, or a combination patent. A challenge to one patent does not establish freedom to launch.
The competitive landscape includes:
- generic pharmaceutical companies pursuing ivacaftor tablets or oral granules;
- Vertex, as the originator and principal patent holder;
- developers of alternative CFTR potentiators;
- companies developing CFTR corrector combinations; and
- developers of mutation-agnostic or genetic therapies.
No biosimilar pathway applies to Kalydeco. Ivacaftor is a chemically synthesized small molecule. Competitive entry would occur through an ANDA or a full new drug application, not a biosimilar application under the Public Health Service Act.
What litigation and settlement issues affect Patent 8,354,427?
A Paragraph IV notice could trigger a 30-month stay of ANDA approval if Vertex filed a timely infringement action. The litigation would likely focus on claim construction, the validity of genotype-specific use claims and the proposed generic label.
Potential settlement structures could include:
- an agreed generic launch date before patent expiration;
- a license limited to non-R117H uses;
- a label restriction excluding R117H treatment;
- a supply or authorized-generic arrangement; or
- a license tied to expiration of composition or formulation patents.
A settlement involving one ivacaftor patent would not necessarily clear the entire estate. A generic may still face separate patents directed to composition, formulation, combinations, pediatric presentations or manufacturing processes.
What generic launch scenarios exist for ivacaftor?
| Scenario |
Likely timing |
Risk profile |
| Full-label generic before patent expiration |
Only after successful challenge, license or settlement |
High patent and litigation exposure |
| Skinny-label generic excluding R117H |
Potentially before method-patent expiration |
Depends on use code and promotional conduct |
| Generic after composition patent expiry but before method expiry |
Possible if label avoids protected use |
Requires separate patent analysis |
| Authorized generic |
Controlled by Vertex or a licensee |
Lower litigation risk |
| Post-expiration full-label generic |
After relevant patent barriers end |
Lowest patent risk |
The central launch question is not whether a generic contains ivacaftor. It is whether its approved label, marketing conduct and actual commercial use support treatment of R117H patients.
How does Patent 8,354,427 compare with broader CFTR patent protection?
Patent 8,354,427 is narrower than an ivacaftor composition patent and narrower than a broad combination patent.
| Patent type |
Breadth |
Primary enforcement target |
| Ivacaftor composition patent |
Broad across uses |
Manufacture, sale and use of ivacaftor |
| R117H method patent |
Narrow genotype-specific use |
Full-label generic or R117H promotion |
| Combination patent |
Product- and regimen-specific |
Multi-active CFTR products |
| Formulation patent |
Dosage-form-specific |
Tablets, granules and manufacturing |
| Manufacturing patent |
Process-specific |
API suppliers and finished-dose manufacturers |
The R117H patent is therefore an indication patent within a layered estate. Its commercial importance depends on the remaining life of composition and formulation patents, the size of the R117H population, and the labeling strategy used by generic applicants.
Key Takeaways
- U.S. Patent 8,354,427 covers treating cystic fibrosis with ivacaftor in patients carrying the CFTR R117H mutation.
- Claim 1 covers both heterozygous and homozygous R117H patients.
- Claims 2 and 3 narrow claim 1 by specifying heterozygous and homozygous status.
- The patent does not claim ivacaftor itself, all CFTR mutations, all CFTR modulators or any particular formulation.
- The nominal expiration date is approximately March 20, 2029, subject to the official USPTO term record.
- The patent is relevant to Kalydeco’s Orange Book method-of-use protection.
- A generic could consider a Paragraph IV certification or a section viii carve-out, depending on the listed use code and proposed label.
- No biosimilar pathway applies because ivacaftor is a small-molecule drug.
- Full commercial clearance requires separate analysis of composition, formulation, combination and manufacturing patents.
FAQs About U.S. Patent 8,354,427 and Ivacaftor
Does Patent 8,354,427 cover Trikafta?
Not by its claim language alone. Trikafta contains ivacaftor, but the patent claims a method of treating R117H cystic fibrosis with ivacaftor. Trikafta’s combination-product and formulation patents must be analyzed separately.
Can a generic sell ivacaftor without infringing the R117H patent?
Potentially. A generic that omits the R117H indication and avoids conduct encouraging that use may have a non-infringement position, subject to the Orange Book use code and the final FDA label.
Does the patent cover patients with only one R117H allele?
Yes. Claim 1 is not limited to homozygous patients. Claim 2 expressly addresses heterozygous patients.
Is R117H a CFTR gating mutation?
R117H is a CFTR mutation associated with impaired channel function and variable clinical severity. Ivacaftor’s FDA-approved use depends on the mutation being classified as responsive under the applicable labeling.
What is the difference between the R117H patent and an ivacaftor composition patent?
The R117H patent protects a specific therapeutic use. A composition patent protects the ivacaftor molecule itself and generally reaches a broader range of products and indications.
References
-
United States Patent and Trademark Office. (2013). U.S. Patent No. 8,354,427, Methods of treating cystic fibrosis transmembrane conductance regulator mediated diseases. U.S. Department of Commerce.
-
U.S. Food and Drug Administration. (2024). Kalydeco (ivacaftor) prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA, Orange Book.
-
United States Patent and Trademark Office. (2008). U.S. Patent No. 7,405,323, Quinoline compounds. U.S. Department of Commerce.
-
Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).
-
35 U.S.C. §§ 154, 271(e), 282.
